Form 4 for EOLS Evolus, Inc.
Accepted 2023-02-06 00:00:00 ET · period of report 2021-08-12 · accession 0001387131-23-001468 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2023-02-06 | 2021-08-12+ | EOLS | Medytox Inc. | 10% | P - Purchase | $11.04 | +37.0K | 7.30M | +0.5% | +$408.8K |
| I | 2023-02-06 | 2023-01-20 | EOLS | Medytox Inc. | 10% | S - Sale | $11.04 | -37.0K | 7.26M | -0.5% | -$409.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.00001 par value per share | 2021-08-12 | P | A | 23,000 | $10.99 | 7,282,500 | I See Footnote | — | — | (F1) Inadvertently filed late due to an administrative error. (F2) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.88 to $11.10, inclusive. The reporting person undertakes to provide to Evolus, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes 1 to 2. (F4) The Issuer shares were previously held of record by Medytox Korea Co., Ltd. ("Medytox Korea"). Medytox, Inc. owns 100% of Medytox Korea. Accordingly, Medytox, Inc. may be deemed to beneficially own indirectly the shares by reason of Medytox Korea's direct beneficial ownership. |
| 2 | Common | Common Stock, $0.00001 par value per share | 2023-01-20 | S | D | 37,043 | $11.04 | 7,259,500 | I See Footnote | — | — | (F1) Inadvertently filed late due to an administrative error. (F4) The Issuer shares were previously held of record by Medytox Korea Co., Ltd. ("Medytox Korea"). Medytox, Inc. owns 100% of Medytox Korea. Accordingly, Medytox, Inc. may be deemed to beneficially own indirectly the shares by reason of Medytox Korea's direct beneficial ownership. |
| 3 | Common | Common Stock, $0.00001 par value per share | 2021-08-13 | P | A | 14,043 | $11.11 | 7,296,543 | I See Footnote | — | — | (F1) Inadvertently filed late due to an administrative error. (F3) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.91 to $11.26, inclusive. (F4) The Issuer shares were previously held of record by Medytox Korea Co., Ltd. ("Medytox Korea"). Medytox, Inc. owns 100% of Medytox Korea. Accordingly, Medytox, Inc. may be deemed to beneficially own indirectly the shares by reason of Medytox Korea's direct beneficial ownership. |